BCL2 and cancer: For example, BCL-2 is overexpressed in 85% of cases of luminal cancers (ER+),30 whereas overexpressed in approximately 41% of TNBC cases,5 which could explain the least sensitivity of MDA-MB-231 cells to VCX.